Related Experiment Videos
Compound 64716, a new synthetic antibacterial agent
Antimicrobial Agents and Chemotherapy
|October 1, 1973
Summary
A novel synthetic antibacterial agent, Compound 64716, demonstrates potent activity against gram-negative bacteria common in urinary tract infections. Its efficacy and favorable pharmacokinetic profile suggest it is a promising therapeutic candidate.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Microbiology
Background:
- Urinary tract infections (UTIs) are frequently caused by gram-negative bacteria.
- Development of new antibacterial agents with improved efficacy and safety profiles is crucial.
Purpose of the Study:
- To evaluate the antibacterial activity and pharmacological properties of a new synthetic compound, 64716.
- To compare Compound 64716 with existing antibacterial agents like nalidixic acid.
Main Methods:
- In vitro determination of minimal inhibitory concentration (MIC) and bactericidal activity against bacterial isolates.
- In vivo efficacy studies in experimental mouse infections.
- Pharmacokinetic analysis of blood and urine concentrations after oral administration.
- Assessment of protein binding and in vitro resistance selection.
Main Results:
- Compound 64716 exhibited potent activity against gram-negative bacteria, including Escherichia coli and Proteus sp., with low MIC values.
- In vivo studies showed comparable therapeutic doses to nalidixic acid, with significantly higher urine concentrations.
- Compound 64716 displayed lower human serum protein binding and did not select for resistant bacteria at high concentrations.
Conclusions:
- Compound 64716 is a promising synthetic antibacterial agent for treating UTIs.
- Its superior antibacterial activity and pharmacological properties compared to nalidixic acid warrant further investigation.